Treatment of Focal Segmental Glomerulosclerosis Recurrence in the Renal Allograft: A Report of Two Cases.
Focal segmental glomerulosclerosis (FSGS) causes glomerular lesions that can progress to end-stage renal disease. It is suspected to be caused by a circulating factor that is amenable to plasmapheresis removal and exhibits a risk for recurrence in the renal allograft. We present two patients with FSGS recurrence in their allograft kidneys diagnosed by biopsy after significant proteinuria developed in the posttransplant setting. Treatment with therapeutic plasma exchange induced long-term remission in both patients. Spot urine protein:creatinine ratios were monitored and treatment was continued until a target of <0.5 was achieved. In patient number two, a second peak in proteinuria and azotemia was ultimately attributable to ureteral stenosis and these values normalized following repair. In conclusion, therapeutic plasma exchange is an effective treatment for FSGS recurring following renal transplant.
Department of Pathology and Laboratory Medicine, UC Irvine Health School of Medicine, USA.
Minh-Ha
MH
Tran
Department of Pharmacy, UC Irvine Health Medical Center, Inpatient Pharmacy, Orange, Calif., USA.
Cynthia
C
Chan
UCLA Olive View, University of Southern California, Los Angeles, Calif., USA.
Whitney
W
Pasch
Department of Pathology and Laboratory Medicine, UC Irvine Health School of Medicine, USA; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, Calif., USA.
Philip
P
Carpenter
Division of Transplantation, Department of Surgery, UC Irvine Health School of Medicine, Orange, Calif., USA.
Hirohito
H
Ichii
Division of Transplantation, Department of Surgery, UC Irvine Health School of Medicine, Orange, Calif., USA.
Clarence
C
Foster
Complications of kidney transplantation; Focal segmental glomerulosclerosis; Intravenous immune globulin; Kidney transplantation; Renal allograft; Rituximab; Therapeutic plasma exchange